Disclaimer
This is a non-independent marketing communication commissioned by Schroder Investment Management. The report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on the dealing ahead of the dissemination of investment research.
In this episode of Trust Issues, we speak to Ailsa Craig & Marek Poszepczynski, managers of International Biotechnology (IBT), about the opportunity for investors in the biotech sector, from the implications of a Trump victory to the current state of play on obesity drugs.
00:00 Introduction
00:19 Overview of IBT and current allocations
02:24 Change in composition of XBI
03:25 Benefits of a basket approach
05:06 Most exciting developments in the biotech sector
07:25 Can other companies compete with Eli Lilly and Novo Nordisk on obesity drugs?
08:49 Recent allocation changes due to the market cycle
12:26 Views on current valuations
15:12 Outlook for M&A
17:09 Outlook for IPO market in 2025
18:13 What IBT offers beyond a passive strategy
19:45 Implications of a Trump administration
21:26 Impact of rate cuts on the portfolio and wider sentiment
22:16 Further information
22:43 Risk warning
Kepler Trust Intelligence provides research and information for professional and private investors. In order to ensure that we provide you with the right kind of content, and to ensure that the content we provide is compliant, you need to tell us what type of investor you are.
Continue